All In Biotech

NDA 211413 · Hq Spclt Pharma

Cefazolin Sodium

Cefazolin Sodium · Intravenous

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 8, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

207

37 Phase 3, 20 recruiting

FAERS reports

12,207

11,391 serious, 1,402 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 27, 2026.

Cefazolin for Injection is a cephalosporin antibacterial indicated for perioperative prophylaxis in adult patients (1.1). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (1.2). 1.1 Perioperative Prophylaxis Cefazolin for Injection is indicated for perioperative prophylaxis in adult patients [see Dosage and Administration (2.1, 2.2, 2.3) . The perioperative use of Cefazolin for Injection is indicated in adult surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric...

Mechanism: Cefazolin is an antibacterial drug [see Microbiology (12.4)] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2026 Supplement 3 · Efficacy LetterLabel
  • May 8, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • CEFAZOLIN SODIUM · CEFAZOLIN SODIUM EQ 3GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
  • CEFAZOLIN SODIUM · CEFAZOLIN SODIUM EQ 2GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefazolin" as an intervention, any sponsor and status, largest first.

All 207 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension711
  • drug ineffective679
  • anaphylactic reaction659
  • anaphylactic shock622
  • rash600
  • pyrexia518
  • renal failure488
  • acute kidney injury442
  • off label use424
  • pain417
  • nausea379
  • urticaria361

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004222
2005210
2006255
2007157
2008238
2009224
2010233
2011507
2012462
2013268
2014304
2015373
2016540
2017510
2018700
2019831
2020855
2021805
2022954
20231,008
2024981
2025956
2026614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cefazolin Sodium* (Cefazolin Sodium)

2024 spending

$4.4M

Beneficiaries

20,069

82,069 claims

Per beneficiary

$218

$2.07 per unit

View as table
YearSpending
2020$4,102,820
2021$4,361,176
2022$4,768,566
2023$5,203,753
2024$4,371,640

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 629 on PubMed

Sponsor: Hq Spclt Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.